Skip to main content
Premium Trial:

Request an Annual Quote

Novacyt Acquires Instrument Manufacturer IT-IS for £10.1M

NEW YORK ─ Novacyt on Thursday announced the acquisition of IT-IS International, the exclusive manufacturer of its q16 and q32 rapid PCR instruments.

Paris-based Novacyt will pay £10.1 million ($13.1 million) in cash upfront for the issued share capital of IT-IS and business assets of IT-IS Life Science (Ireland).

The acquisition of Stokesley, UK-based IT-IS, a private diagnostic instrument development and manufacturing company founded in 2004, secures important intellectual property for its q16 and q32 rapid-PCR instruments for near-patient testing of COVID-19, Novacyt said. The acquisition further expands its core capabilities in instrument manufacturing and product offerings in mobile PCR devices, the firm added.

"IT-IS has established a reputation as experts in the development of mobile and rapid PCR instruments," Graham Mullis, group CEO of Novacyt, said in a statement. "This acquisition ensures that Novacyt is in a strong position to fulfill the growing market demands for rapid near-patient testing of COVID-19, as well as other infectious diseases."

Novacyt said that as a result of this acquisition, it will become a diagnostic platform instrument and reagent manufacturer and will significantly increase the manufacturing capability of IT-IS to manage the expected demand for its q16 and q32 PCR instruments.

As a result of higher manufacturing volume, Novacyt expects to reduce its cost of goods and therefore improve the gross margin of its instrument sales.

Novacyt added that the COVID-19 pandemic presents it with a significant opportunity to place rapid mobile testing instruments as shortages in testing capacity and limitations of laboratory-based testing drives healthcare away from large centralized platforms.

The acquisition of IT-IS includes customers, suppliers, software, patents, trademarks, contracts, stocks, technical files, and know-how to design, manufacture, distribute, and market IT-IS's commercial product portfolio. The product portfolio includes IT-IS-branded MyGo Mini and MyGo Pro PCR instruments.

Novacyt said that the acquisition is immediately accretive to earnings. IT-IS posted revenues of £3.9 million and a net profit of £800,000 for fiscal year 2019, and revenues are expected to increase to £5.0 million for fiscal year 2020.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.